Suppr超能文献

全甲状腺切除术后使用未刺激血清甲状腺球蛋白水平和甲状腺球蛋白倍增率对甲状腺乳头状癌进行动态风险评估

Dynamic Risk Assessment Using Unstimulated Serum Thyroglobulin Level and Thyroglobulin Doubling Rate after Total Thyroidectomy for Papillary Thyroid Carcinoma.

作者信息

Ito Yasuhiro, Miyauchi Akira, Yamamoto Masashi, Kihara Minoru, Onoda Naoyoshi, Miya Akihiro

机构信息

Department of Surgery, Kuma Hospital, Kobe, Japan.

出版信息

Thyroid. 2025 Aug 11. doi: 10.1177/10507256251367242.

Abstract

Thyroglobulin (Tg), stimulated or unstimulated by recombinant human thyrotropin (TSH), is a static marker of recurrent or persistent disease, and the Tg-doubling rate (Tg-DR) is a dynamic prognostic factor. This study evaluated the prognostic value of an unstimulated Tg (uTg) and Tg-DR papillary thyroid carcinoma (PTC). This retrospective study included 1818 Tg antibody (Tg-Ab)-negative patients who underwent curative intent total thyroidectomy for PTC without distant metastasis. The uTg was measured 1-3 months post-surgery under TSH suppression (<0.1 mIU/mL). We calculated the Tg-DR for patients, of whom postoperative Tg levels could be measured three or more times under TSH suppression. Eighty-eight (4.8%) and 32 (1.8%) patients had respective local and distant recurrences (median follow-up period, 7.2 years; 25th percentile 4.7 years, 75th percentile 9.8 years). Of 1818 patients, 131 had a uTg ≥3 ng/mL and were more likely to display local and distant recurrences in univariate and multivariable analyses ( < 0.001). We divided 1212 patients with no adjuvant radioactive iodine treatment, of whom uTg and Tg-DR data were available, into four categories A, uTg ≥3 ng/mL and Tg-DR ≥0.33/year; B, uTg <3 ng/mL and Tg-DR ≥0.33/year; C, uTg ≥3 ng/mL and Tg-DR <0.33/year; and D, uTg <3 ng/mL and Tg-DR <0.33/year. The lymph node recurrence-free survival rate was significantly worse from category A to D (A vs. B, < 0.001, hazard ratio or HR [CI]: 5.083 [1.994-12.955]; B vs. C, = 0.001, HR [CI]: 2.654 [1.462-4.824]; C vs. D, < 0.001, HR [CI]: 27.420 [15.100-4.980]). The distant recurrence-free survival rate (DR-FS) of category B did not differ from that of category C ( = 0.419), but DR-FS of category D was better ( < 0.001) than those of B and C, and that of category A tended to be worse ( = 0.087) compared with those of B and C. Patients in category A, categories B and C, and category D could thus be classified as high-risk, intermediate-risk, and low-risk for distant recurrence, respectively. This study demonstrates the prognostic value of postoperative uTg and Tg-DR in Tg-Ab-negative patients with PTC under TSH suppression after total thyroidectomy. Prospective studies are needed to confirm these findings.

摘要

在重组人促甲状腺激素(TSH)刺激或未刺激的情况下,甲状腺球蛋白(Tg)是复发或持续性疾病的静态标志物,而Tg倍增率(Tg-DR)是一个动态预后因素。本研究评估了未刺激的Tg(uTg)和Tg-DR在甲状腺乳头状癌(PTC)中的预后价值。这项回顾性研究纳入了1818例Tg抗体(Tg-Ab)阴性且因PTC接受了根治性全甲状腺切除术且无远处转移的患者。术后1至3个月,在TSH抑制状态下(<0.1 mIU/mL)测量uTg。我们计算了术后在TSH抑制状态下可测量三次或更多次Tg水平的患者的Tg-DR。88例(4.8%)和32例(1.8%)患者分别出现局部和远处复发(中位随访期7.2年;第25百分位数4.7年,第75百分位数9.8年)。在1818例患者中,131例uTg≥3 ng/mL,在单因素和多因素分析中更有可能出现局部和远处复发(<0.001)。我们将1212例未接受辅助放射性碘治疗且有uTg和Tg-DR数据的患者分为四类:A类,uTg≥3 ng/mL且Tg-DR≥0.33/年;B类,uTg<3 ng/mL且Tg-DR≥0.33/年;C类,uTg≥3 ng/mL且Tg-DR<0.33/年;D类,uTg<3 ng/mL且Tg-DR<0.33/年。从A类到D类,无淋巴结复发生存率显著变差(A类与B类比较,<0.001,风险比或HR[CI]:5.083[1.994 - 12.955];B类与C类比较,=0.001,HR[CI]:2.654[1.462 - 4.824];C类与D类比较,<0.001,HR[CI]:27.420[15.100 - 4.980])。B类的无远处复发生存率(DR-FS)与C类无差异(=0.419),但D类的DR-FS优于B类和C类(<0.001),A类的DR-FS与B类和C类相比倾向于更差(=0.087)。因此,A类、B类和C类以及D类患者可分别归类为远处复发的高风险、中风险和低风险患者。本研究证明了术后uTg和Tg-DR在全甲状腺切除术后TSH抑制状态下Tg-Ab阴性PTC患者中的预后价值。需要前瞻性研究来证实这些发现。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验